Nov 24, 2020 09:20 PM (GMT+8) · EqualOcean
Nanxin pharmaceutical announced that with the promotion of the company's R & D work, in order to meet the needs of product pilot test, technical improvement and subsequent approved products, and in combination with the company's strategic development goals, it plans to invest about 431 million yuan in the plant area of Guangzhou Nanxin Pharmaceutical Co., Ltd. to construct the third phase project of paramivir production base, of which 326 million yuan is to be used as the over raised fund, and the remaining part will be invested by the company The company invests with its own funds or self raised funds.

This text is a result of machine translation.